Peptide News Digest

#Outsourcing-Facility

2 stories

Regulatory · View digest

FDA Public Comment Period on the April 30, 2026 Proposed Rule to Permanently Exclude Semaglutide, Tirzepatide, and Liraglutide From the Section 503B Bulks List Closed Thursday July 30, 2026 After a Federal Register-Extended Deadline From the Original June 29 Cutoff; The FDA Found No Clinical Need for Outsourcing Facilities to Compound the Three GLP-1 Molecules From Bulk Drug Substances; Finalization of the Rule Would Close the Last Legal Pathway for Large-Scale FDA-Registered 503B Outsourcing Facility Compounding of the Branded GLP-1s, Following the December 2024 Semaglutide Shortage Resolution and February 2025 Tirzepatide Shortage Resolution

The FDA public comment period on the April 30, 2026 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List closed Thursday July 30, 2026 after a Federal Register-extended deadline from the original June 29 cutoff. The FDA's underlying finding: no clinical need for FDA-registered outsourcing facilities to compound the three GLP-1 molecules from bulk drug substances. Section 503B outsourcing facilities are the FDA-registered large-scale compounding manufacturers (as distinct from state-licensed 503A pharmacies that compound for individual patient prescriptions). Finalization of the proposed rule would close the last legal pathway for large-scale FDA-registered 503B outsourcing facility compounding of the branded GLP-1 molecules, following the December 2024 semaglutide shortage resolution and February 2025 tirzepatide shortage resolution that ended the shortage-based compounding pathway. FDA rulemaking to finalize the exclusion after comment-period close typically takes 3-9 months depending on the volume and substance of received comments. Telehealth platforms including Hims & Hers Health (NYSE: HIMS) and LifeMD have already migrated to branded supply through Novo Nordisk and Eli Lilly commercial channels ahead of the expected 503B closure. FDA Adverse Event Reporting System (FAERS) data as of the July 2026 safety statement: 990 adverse events linked to compounded semaglutide, over 730 for compounded tirzepatide.

Regulatory · View digest

FDA Public Comment Period Closes Thursday July 30, 2026 on the April 30, 2026 Proposed Rule to Permanently Exclude Semaglutide, Tirzepatide, and Liraglutide From the Section 503B Bulks List, Which Would Close the Last Legal Pathway for Large-Scale FDA-Registered Outsourcing Facility Compounding of the Branded GLP-1 Molecules; Docket Followed the FDA Category-2-Unwind Timeline That Also Culminated in the July 23-24 Pharmacy Compounding Advisory Committee (PCAC) Vote Recommending 6 of 7 Peptides for Section 503A Bulks List Inclusion

The FDA public comment period on the April 30, 2026 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List closed Thursday July 30, 2026. If the FDA finalizes the rule, large-scale FDA-registered 503B outsourcing facilities will no longer be able to legally prepare compounded semaglutide, tirzepatide, or liraglutide once the shortage-based compounding pathway has fully closed. The 503B exclusion is the parallel-track regulatory action to the July 23-24 PCAC vote on the 7 research peptides for the 503A Bulks List. Where 503A operates under state pharmacy board licensure for individual-patient prescriptions, 503B operates under FDA registration for bulk manufacturing at outsourcing facilities. The 503A vote broadened access to 6 of 7 research peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon; DSIP rejected). The 503B exclusion narrows access for the branded GLP-1 franchise. Both actions require FDA rulemaking to formalize, with typical timelines of 6-18 months from the date the agency decides to act. Telehealth companies including Hims & Hers Health (NYSE: HIMS) and LifeMD (NASDAQ: LFMD) have already migrated to branded supply through Novo Nordisk and Eli Lilly commercial channels ahead of the expected 503B closure.